Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Efficacy and Safety of Anlotinib Plus Pemetrexed as the 1-line Treatment of Patients With Platinum Intolerant Advanced Non-squamous NSCLC, With Pemetrexed Control.

NCT03768037 is registered in ClinicalTrials.gov with Guangdong Association of Clinical Trials as lead sponsor.

NCT NCT03768037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03768037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Efficacy and Safety of Anlotinib Plus Pemetrexed as the 1-line Treatment of Patients With Platinum Intolerant Advanced Non-squamous NSCLC, With Pemetrexed Control.
Lead sponsor
Guangdong Association of Clinical Trials
Phase
Phase 4
Overall status
Unknown status
Start date
November 26, 2018
Completion date
November 26, 2020
Enrollment
106 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-squamous nsclc